An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia
Status:
Recruiting
Trial end date:
2022-06-20
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled parallel group 3-arm study assessing efficacy,
safety, and tolerability of two doses BXCL501 in male and female geriatric residents (65
years and older) with acute agitation associated with all forms of dementia (i.e., probably
Alzheimer's Disease, vascular dementia; mixed; frontotemporal dementia) excluding
Parkinson's-Related Dementia and Lewy Body Dementia.